激活PKC-ε会诱导HIV的表达,并提高耐受性
Alivelu M Irrinki1, Jasmine Kaur1, Bally Randhawa1
1Gilead Sciences, Inc., Foster City, California, United States of America.
PLoS pathogens
|February 6, 2025
概括
科学家们开发了一种新药,C-233,可以安全地激活潜伏的HIV储存库. 这种新型蛋白质激酶C (PKC) 激动剂通过降低毒性来改善HIV潜伏逆转疗法.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 尽管进行抗逆转录病毒疗法 (ART),但HIV-1仍会建立潜在的储存库,需要终身治疗.
- 在ART期间激活潜伏的HIV可能会增强免疫介导的感染细胞的消除.
- 蛋白激酶C (PKC) 异酶可以增加HIV转录,使它们成为潜在的延迟逆转剂.
研究的目的:
- 调查PKC激活的毒性,并开发选择性PKC激动剂,以安全地逆转HIV潜伏期.
- 为了确定参与T细胞激活和潜在的目标外影响的PKC异型.
主要方法:
- 用PKC激动剂对来自HIV感染者的CD4+T细胞进行活体治疗.
- 基于结构的药物设计,以创建一种新的,选择性的PKC激动剂 (C-233).
- 对T细胞和血小板激活,HIVRNA和p24表达的评估.
主要成果:
- 在T细胞激活度下,PKC激活导致显著的血小板激活和传播的血管内凝固的迹象.
- PKC-ε和PKC-η异型在CD4+T细胞中高度表达,但不是血小板.
- 新型激素C-233选择性地激活PKC-ε,显示T细胞激活的功效是血小板激活的5倍.
- 在CD4+T细胞中,C-233增加了HIVRNA和p24表达.
结论:
- 基于结构的药物设计可以产生具有改善安全性概况的选择性PKC激动剂.
- 选择性PKC激动剂,如C-233,为安全的HIV潜伏逆转提供了一个有希望的策略.
- 针对性地激活艾滋病毒储存库可能会提高艾滋病毒治愈策略的耐受性和有效性.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
5.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.1K
01:25cAMP-dependent Protein Kinase Pathways
7.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.3K